Aliases:This biomarker is also known as:
- obese, mouse, homolog of,
- obesity factor,
- leptin (obesity homolog, mouse),
- leptin (murine obesity homolog),
Leptin (LEP) is secreted by white adipocytes and plays a major role in the regulation of body weight. This protein, which acts through the leptin receptor, functions as part of a signaling pathway that can inhibit food intake and/or regulate energy expenditure to maintain constancy of the adipose mass. Leptin has also been implicated in the regulation of reproduction, glucose homeostasis, bone formation, wound healing and the immune system. Leptin has several endocrine functions and is also involved in the regulation of immune and inflammatory responses, hematopoiesis, angiogenesis and wound healing. Mutations in the leptin gene and/or its regulatory regions cause severe obesity and morbid obesity with hypogonadism. The leptin gene has also been linked to type 2 diabetes mellitus development.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
Leptin is secreted by white adipocytes. Adipose tissue is currently considered a biologically active endocrine organ, secreting a variety of bioactive adipokines, such as leptin, adiponectin, resistin and nicotinamide phosphoribosyl-transferase/visfatin. Current research has shown that the combination of obesity, insulin resistance and adipokines is associated with the risk and prognosis of postmenopausal breast cancer.
LEP, or leptin, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
Leptin, a secreted protein of the ob gene by white adipose tissue, plays an important role in the regulation of food intake and energy consumption in the brain and acts as a potential growth stimulator in normal and neoplastic breast cancer cells. The expression of leptin receptors in immortalized ovarian surface epithelium (IOSE) and ovarian cancer cell lines, and potential effect of leptin on the cell growth and activation of mitogen-activated protein kinases (MAPKs) in the BG-1 ovarian cancer cell line has been tested. Both short and long isoforms of leptin receptors are expressed in IOSE-80PC (a post-crisis line), BG-1, OVCAR-3, and SKOV-3 cells. In addition, treatment with leptin resulted in the growth stimulation of BG-1 cells, an activation of ERK1/2 and inhibition of constitutive phosphorylation of p38 MAPK.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. LEP alone was not a strong predictor.
- Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets.
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.